Literature DB >> 18832863

Disposition of naltrexone after intravenous bolus administration in Wistar rats, low-alcohol-drinking rats and high-alcohol-drinking rats.

Emmanuel O Akala1, Hu Wang, Adedayo Adedoyin.   

Abstract

Reports have shown that interspecies differences in the metabolism and pharmacokinetics of naltrexone are a rule rather than exception. However, there is paucity of information on the disposition of naltrexone in selectively bred rat lines that reliably exhibit high and low voluntary alcohol consumption, and are often used to study alcohol-drinking behavior. We have characterized the pharmacokinetic profiles of naltrexone in selectively bred rat lines: high-alcohol-drinking (HAD-1) and low-alcohol-drinking (LAD-1) rats as well as the native Wistar strain. This study was carried out to establish a baseline pharmacokinetic profile of naltrexone in these rats prior to evaluating its pharmacokinetic profile in polymeric controlled-release formulations in our laboratory. The hypothesis is that alcohol-preferring and non-alcohol-preferring lines of rats should differ in the disposition of intravenously administered naltrexone. Naltrexone administration and blood collection were via the jugular vein. In a parallel experiment, naltrexone was administered via the jugular vein, but urine was collected using the Nalgene metabolic cage system. Data were analyzed by a noncompartmental approach. Results show a high clearance that is close to or higher than hepatic blood flow in all groups (Wistar > LAD-1 > HAD-1, but with a statistically significant difference only between Wistar and HAD-1). Volume of distribution (approximately 2.5-3 l/kg) and the half-life (approximately 1 h) were similar. Urinary elimination of naltrexone was small, but also showed differences between the rats: HAD-1 > LAD-1 > Wistar, but with a statistically significant difference only between HAD-1 and Wistar rats. This study has therefore established the baseline disposition characteristics of naltrexone in these strains of rats. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832863      PMCID: PMC2910369          DOI: 10.1159/000159776

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  29 in total

1.  Gene expression in brain: a window on ethanol dependence, neuroadaptation, and preference.

Authors:  Paula L Hoffman; Michael Miles; Howard J Edenberg; Wolfgang Sommer; Boris Tabakoff; Jeanne M Wehner; Joanne Lewohl
Journal:  Alcohol Clin Exp Res       Date:  2003-02       Impact factor: 3.455

2.  A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.

Authors:  J Chick; R Anton; K Checinski; R Croop; D C Drummond; R Farmer; D Labriola; J Marshall; J Moncrieff; M Y Morgan; T Peters; B Ritson
Journal:  Alcohol Alcohol       Date:  2000 Nov-Dec       Impact factor: 2.826

Review 3.  Phenotypic and genotypic characterization of the Indiana University rat lines selectively bred for high and low alcohol preference.

Authors:  James M Murphy; Robert B Stewart; Richard L Bell; Nancy E Badia-Elder; Lucinda G Carr; William J McBride; Lawrence Lumeng; Ting-Kai Li
Journal:  Behav Genet       Date:  2002-09       Impact factor: 2.805

4.  Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.

Authors:  H R Kranzler; V Modesto-Lowe; J Van Kirk
Journal:  Neuropsychopharmacology       Date:  2000-05       Impact factor: 7.853

5.  In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs.

Authors:  Satyanarayana Valiveti; Dana C Hammell; Kalpana S Paudel; Mohamed O Hamad; Peter A Crooks; Audra L Stinchcomb
Journal:  J Control Release       Date:  2005-02-02       Impact factor: 9.776

6.  Naltrexone in the treatment of alcohol dependence.

Authors:  J H Krystal; J A Cramer; W F Krol; G F Kirk; R A Rosenheck
Journal:  N Engl J Med       Date:  2001-12-13       Impact factor: 91.245

7.  Design of naltrexone-loaded hydrolyzable crosslinked nanoparticles.

Authors:  Wusheng Yin; Emmanuel O Akala; Robert E Taylor
Journal:  Int J Pharm       Date:  2002-09-05       Impact factor: 5.875

8.  Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats.

Authors:  Raymond T Bartus; Dwaine F Emerich; Joyce Hotz; Marc Blaustein; Reginald L Dean; Brigido Perdomo; Anthony S Basile
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

9.  Low-dose stimulatory effects of ethanol during adolescence in rat lines selectively bred for high alcohol intake.

Authors:  Z A Rodd; R L Bell; D L McKinzie; A A Webster; J M Murphy; L Lumeng; T-K Li; W J McBride
Journal:  Alcohol Clin Exp Res       Date:  2004-04       Impact factor: 3.455

10.  A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.

Authors:  David W Oslin; Wade Berrettini; Henry R Kranzler; Helen Pettinati; Joel Gelernter; Joseph R Volpicelli; Charles P O'Brien
Journal:  Neuropsychopharmacology       Date:  2003-06-18       Impact factor: 7.853

View more
  4 in total

1.  Studies on in vitro availability, degradation, and thermal properties of naltrexone-loaded biodegradable microspheres.

Authors:  Emmamuel O Akala; Pornruedee Wiriyacoonkasem; Gaofeng Pan
Journal:  Drug Dev Ind Pharm       Date:  2011-03-30       Impact factor: 3.225

2.  Effects of naltrexone and LY255582 on ethanol maintenance, seeking, and relapse responding by alcohol-preferring (P) rats.

Authors:  Ronnie Dhaher; Jamie E Toalston; Sheketha R Hauser; Richard L Bell; David L McKinzie; William J McBride; Zachary A Rodd
Journal:  Alcohol       Date:  2011-10-01       Impact factor: 2.405

3.  Methylphenidate and μ opioid receptor interactions: a pharmacological target for prevention of stimulant abuse.

Authors:  Jinmin Zhu; Thomas J Spencer; Lee-Yuan Liu-Chen; Joseph Biederman; Pradeep G Bhide
Journal:  Neuropharmacology       Date:  2011-04-23       Impact factor: 5.250

4.  Ethanol Exposure History and Alcoholic Reward Differentially Alter Dopamine Release in the Nucleus Accumbens to a Reward-Predictive Cue.

Authors:  Amanda M Fiorenza; Tatiana A Shnitko; Kaitlin M Sullivan; Sudheer R Vemuru; Alexander Gomez-A; Julie Y Esaki; Charlotte A Boettiger; Claudio Da Cunha; Donita L Robinson
Journal:  Alcohol Clin Exp Res       Date:  2018-04-30       Impact factor: 3.455

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.